Varian TrueBeam Secures Regulatory Clearance for Low-Dose Radiotherapy in Osteoarthritis Treatment

Siemens Healthineers has announced that its Varian TrueBeam radiotherapy systems have obtained FDA 510(k) clearance to administer low-dose radiation therapy (LDRT) for adults suffering from medically refractory osteoarthritis (OA). The TrueBeam systems, including TrueBeam STx, VitalBeam, and Edge, are now authorized for this new application, extending their use beyond cancer treatment into chronic musculoskeletal care. This marks a significant development for patients with severe and persistent osteoarthritis pain.

Osteoarthritis affects more than 33 million individuals in the United States alone, with an estimated global impact on approximately 600 million adults. The condition often leads to chronic pain and decreased mobility. Despite the availability of medication and various treatments, a considerable number of individuals find little relief from these options, prompting the need for alternative therapies. With FDA's approval, LDRT emerges as a viable and non-invasive outpatient option. Recent studies demonstrate LDRT’s potential to target inflammation, alleviate pain, enhance joint function, and possibly delay surgical needs.

Dr Gopal K. Bajaj, emeritus chairman and medical director at Inova Schar Cancer, emphasized the importance of this clearance. "This FDA clearance is a meaningful step toward integrating low-dose radiotherapy into routine care pathways for adults with medically refractory osteoarthritis," said Bajaj. "It gives patients and advocates greater confidence in a clearly defined, regulated treatment option. For clinicians, it supports more consistent referrals and reimbursement discussions while encouraging responsible adoption and real-world outcomes tracking."

The TrueBeam platform is renowned for its precision in imaging and beam delivery, which enables tailored care with high accuracy. These advancements ensure that patients with chronic conditions can now benefit from the system's robust capabilities, similar to its previous use in oncology settings. Arthur Kaindl, head of Varian, expressed that this new clearance exemplifies the company's commitment to broadening the scope of precision radiotherapy to address diverse health care needs, beyond just cancer care.

This addition to Varian's portfolio of non-oncological applications highlights the company's ongoing innovation in medical technologies. Prior non-cancer capabilities include radiosurgery for treating medically refractory essential tremor in adults. As Siemens Healthineers continues to expand its reach, the integration of imaging and therapeutic solutions remains paramount in tackling both oncological and chronic conditions.